

Singapore Diagnostics, Lucence partner to market cancer blood tests in Philippines

13 August 2018 | News

The blood tests are based on Lucence's patented liquid biopsy technology, which detect genetic mutations from tumor DNA circulating in the blood.



Singapore – Lucence Diagnostics, a genomic medicine company focused on inventing advanced cancer diagnostics, and Singapore Diagnostics (Philippines), the largest pure clinical laboratory in the country, announced a partnership to market Lucence's advanced cancer blood tests in the Philippines.

Singapore Diagnostics will distribute Lucence's range of blood tests for cancer diagnosis and treatment in the Philippines. The blood tests are based on Lucence's patented liquid biopsy technology, which detect genetic mutations from tumor DNA circulating in the blood. This allows doctors to select the most appropriate cancer treatment according to the genetic mutations identified.

Compared to conventional tissue biopsy, Lucence's liquid biopsy approach is noninvasive and faster. The tests target the most common cancers in Asia like breast, colon, lung and nasopharyngeal cancer.

Lucence's blood tests can also diagnose early stage nasopharyngeal cancer before symptoms show and check whether a person is predisposed to cancer by detecting genes commonly associated with increased risk of cancer.

According to the Philippine Statistics Authority, one out of every 10 deaths in the country is caused by cancer. Singapore Diagnostics is one the largest laboratories in the Philippines handling 200,000 tests every month. It is part of a group of regional laboratories operating in Singapore, Malaysia and Hong Kong. Singapore Diagnostics currently serves 500 hospital and clinic laboratory sites in Metro Manila. With this partnership, Lucence's cancer blood tests will now be made available to all its customers in the Philippines.

"We are delighted to work with Lucence to provide their advanced cancer blood tests in the Philippines. Singapore

Diagnosics always strives to be at the forefront of innovation in our industry by seeking out the latest medical technologies and exploring its applications in clinical settings. Through our partnership with Lucence, we can now provide the most advanced cancer technology for cancer detection and treatment to our customers. We look forward to working closely with Lucence to drive better cancer care in the Philippines,” said Mr. Ritche Evidente, CEO, Singapore Diagnostics.